{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:31:34Z","timestamp":1791394294058,"version":"4.3.3"},"reference-count":43,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001868","name":"NSC","doi-asserted-by":"publisher","award":["98A1-VCSP01-014"],"award-info":[{"award-number":["98A1-VCSP01-014"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.vaccine.2014.08.064","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T17:28:43Z","timestamp":1410802123000},"page":"6177-6182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases"],"prefix":"10.1016","volume":"32","author":[{"given":"Chia-Chyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pele","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.08.064_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","article-title":"An overview of the evolution of enterovirus 71 and its clinical and public health significance","volume":"26","author":"McMinn","year":"2002","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","article-title":"Virology, epidemiology, pathogenesis and control of enterovirus 71","volume":"10","author":"Solomon","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2014.08.064_bib0015","doi-asserted-by":"crossref","first-page":"e1737","DOI":"10.1371\/journal.pntd.0001737","article-title":"Challenges to licensure of enterovirus 71 vaccines","volume":"6","author":"Lee","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJMp1400601","article-title":"Enterovirus vaccines for an emerging cause of brain-stem encephalitis","volume":"370","author":"McMinn","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4161\/hv.27087","article-title":"Coxsackievirus A16: epidemiology, diagnosis and vaccine","volume":"10","author":"Mao","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0030","doi-asserted-by":"crossref","first-page":"19780","DOI":"10.3402\/ehtj.v6i0.19780","article-title":"Human enterovirus 71 epidemics: what's next?","volume":"6","author":"Yip","year":"2013","journal-title":"Emerg Health Threats J"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.meegid.2009.05.010","article-title":"Phylogenetic designation of EV71 genotypes and subgenotypes using complete genome sequences","volume":"10","author":"Chan","year":"2010","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0040","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.00630-09","article-title":"Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008","volume":"47","author":"Huang","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.08.064_bib0045","doi-asserted-by":"crossref","first-page":"e90624","DOI":"10.1371\/journal.pone.0090624","article-title":"Molecular comparison and evolutionary analysis of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity","volume":"9","author":"Bessaud","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.064_bib0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11684-012-0237-z","article-title":"Progress on the research and development of human enterovirus 71 (EV71) vaccines","volume":"7","author":"Liang","year":"2013","journal-title":"Front Med"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0055","series-title":"Vaccine","first-page":"625","article-title":"Poliovirus vaccine-inactivated","author":"Plotkin","year":"2004"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/hv.21739","article-title":"Production of EV71 vaccine candidates","volume":"8","author":"Chong","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0065","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.vaccine.2013.03.015","article-title":"A phase 1, randomized, open-label study to evaluate the safety and immunogenicity of enterovirus 71 vaccine","volume":"31","author":"Cheng","year":"2013","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2014.08.064_bib0070","doi-asserted-by":"crossref","first-page":"e79783","DOI":"10.1371\/journal.pone.0079783","article-title":"Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody responses against subgenotypes B1, B4, B5 and C4A in adult volunteers","volume":"8","author":"Chou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0075","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0080","doi-asserted-by":"crossref","first-page":"e79599","DOI":"10.1371\/journal.pone.0079599","article-title":"The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children","volume":"8","author":"Mao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in health children","volume":"370","author":"Li","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/14760584.2014.897617","article-title":"Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials","volume":"13","author":"Li","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0095","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0100","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4161\/hv.28397","article-title":"Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large scale phase 3 clinical trial","volume":"105","author":"Chen","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0105","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1016\/j.vaccine.2011.01.094","article-title":"Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine","volume":"29","author":"Chen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0110","article-title":"A booster dose of an inactivated enterovirus 71 vaccine in Chinese young children: a randomized, double-blind, placebo-controlled clinical trial","author":"Wang","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.064_bib0115","doi-asserted-by":"crossref","first-page":"e96051","DOI":"10.1371\/journal.pone.0096051","article-title":"Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot and mouth disease in central China","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.vaccine.2014.08.064_bib0120","doi-asserted-by":"crossref","first-page":"e49973","DOI":"10.1371\/journal.pone.0049973","article-title":"Immunological and biochemical characterization of coxsackievirus A16 viral particles","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0125","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2011.04.010","article-title":"Identification and characterization of a cross-neutralization epitope of EV71","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0130","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.vaccine.2014.03.012","article-title":"A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits a balanced protective immunity against both viruses","volume":"32","author":"Cai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0135","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/670506","article-title":"Immunogenicity studies of bivalent inactivated virions of EV71\/CVA16 formulated with submicron emulsion systems","author":"Lin","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0140","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3201\/eid1802.111147","article-title":"Hand, foot and mouth disease caused by coxsackievirus A6, Japan, 2011","volume":"18","author":"Fujimoto","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(13)70264-0","article-title":"Atyptical hand, foot, and mouth disease: a vesiculobullous eruption caused by coxsackievirus A6","volume":"14","author":"Feder","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2014.08.064_bib0150","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1542\/peds.109.6.e88","article-title":"Risk factors of enterovirus 71 infection and associated hand, foot and mouth disease\/herpangina in children during an epidemic in Taiwan","volume":"109","author":"Chang","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0155","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nm.1992","article-title":"Scavenger receptor B2 is a cellular receptor for enterovirus 71","volume":"15","author":"Yamayoshi","year":"2009","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2014.08.064_bib0160","doi-asserted-by":"crossref","first-page":"e52073","DOI":"10.1371\/journal.pone.0052073","article-title":"Circulation of coxsackievirus A10 and A6 in hand\u2013foot\u2013mouth disease in China, 2009\u20132011","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0165","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1128\/JVI.00020-12","article-title":"Human SCARB2-dependent infection by Coxsackievirus A7, A14 and A16 and enterovirus 71","volume":"86","author":"Yamayoshi","year":"2012","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2014.08.064_bib0170","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1128\/JCM.00007-11","article-title":"Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A","volume":"49","author":"Hu","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0175","doi-asserted-by":"crossref","first-page":"e67157","DOI":"10.1371\/journal.pone.0067157","article-title":"Epidemics and frequent recombination within species in outbreaks of human enterovirus B-associated hand, foot and mouth disease in Shandong China in 2010 and 2011","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jviromet.2011.06.001","article-title":"Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process","volume":"176","author":"Liu","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0185","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2011.04.010","article-title":"Identification and characterization of a cross-neutralization epitope of EV71","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1423-0127-21-31","article-title":"Animal models of enterovirus 71 infection: applications and limitations","volume":"21","author":"Wang","year":"2014","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.064_bib0195","doi-asserted-by":"crossref","first-page":"e57591","DOI":"10.1371\/journal.pone.0057591","article-title":"Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0200","doi-asserted-by":"crossref","first-page":"14753","DOI":"10.1073\/pnas.1217563110","article-title":"Transgenic mouse model for the study of enterovirus 71 neuropathogenesis","volume":"110","author":"Fujii","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0205","first-page":"269858","article-title":"Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice","volume":"8","author":"Chang","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.064_bib0210","doi-asserted-by":"crossref","first-page":"e200005","DOI":"10.1371\/journal.pone.0020005","article-title":"Purification and characterization of EV71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.08.064_bib0215","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1016\/j.vaccine.2010.09.065","article-title":"Forecasting the economic value of an enterovirus 71 (EV71) vaccine","volume":"28","author":"Lee","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14012225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14012225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:30:19Z","timestamp":1565829019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14012225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":43,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0264410X14012225"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}